RAYPID GEMFIBROZIL 600MG 28TABS

$105,410.54

Category:

Description

a) Primary prevention of coronary heart disease (CPC) and myocardial infarction (MI) in patients with hypercholesterolemia.

b) Dyslipidemias types IIa, IIb, and IV, according to the Fredrickson classification.

c) Treatment of other dyslipidemias: Fredrickson’s Types III and V. Associated with diabetes or xanthomas.

Gemfibrozil is indicated when exercise, weight reduction, and dietary or other non-pharmacological measures, such as limiting alcohol intake, have failed. Other medical conditions such as hypothyroidism and diabetes should be controlled as much as possible.

During treatment with Gemfibrozil, periodic determinations of serum lipids should be obtained. The drug should be discontinued or additional treatment should be instituted if the lipid response is inadequate after three months.

RAYPID GEMFIBROZIL 600MG 28TABS

Reviews

There are no reviews yet.

Be the first to review “RAYPID GEMFIBROZIL 600MG 28TABS”

Your email address will not be published. Required fields are marked *

Scroll to top